Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, San-Miguel, Jesus, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Casal, Eva, Srinivasan, Shankar, Yu, Xin, Nguyen, Tuong Vi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179841/
https://www.ncbi.nlm.nih.gov/pubmed/32895455
http://dx.doi.org/10.1038/s41375-020-01021-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179841/
https://www.ncbi.nlm.nih.gov/pubmed/32895455
http://dx.doi.org/10.1038/s41375-020-01021-3

Ejemplares similares